
MaxCyte (MXCT) Stock Forecast & Price Target
MaxCyte (MXCT) Analyst Ratings
Bulls say
MaxCyte Inc. is positioned favorably in the growing Cell and Gene Therapy (CGT) industry, with ongoing innovations in non-viral delivery systems highlighting its relevance and potential within the sector. The company demonstrated resilience, as Cell Therapy revenue exceeded expectations by approximately $0.4 million, indicating robust demand for its proprietary Flow Electroporation platform. Furthermore, the maintained revenue guidance of $6 million underscores MaxCyte's stable financial outlook despite broader market competitiveness.
Bears say
MaxCyte Inc. has revised its revenue expectations, anticipating flat to only modest growth of 5% year-over-year for FY24, following a significant 32% decline in core revenue for FY23, with consumable sales down by 42%. The company reported a preliminary revenue miss for Q3 2023 and has lowered its overall revenue guidance for FY23 to $34 million, indicating persistent operational challenges amplified by macroeconomic pressures. Additionally, a reliance on capital-intensive cell and gene therapy (CGT) markets, along with a history of sustained financial losses, raises concerns about the company's short-term viability and long-term growth prospects.
This aggregate rating is based on analysts' research of MaxCyte and is not a guaranteed prediction by Public.com or investment advice.
MaxCyte (MXCT) Analyst Forecast & Price Prediction
Start investing in MaxCyte (MXCT)
Order type
Buy in
Order amount
Est. shares
0 shares